Table 4 Regression analysis of early tumor recurrence and recurrence free survival (n=76)

Age, years (continuous)

0.997

0.943-1.054

0.916

0.985

0.957-1.014

0.306

Gender, male vs. female

1.320

0.482-3.615

0.589

0.889

0.503-1.570

0.684

Diabetes mellitus, yes vs. no

0.373

0.097-1.436

0.152

0.710

0.353-1.427

0.336

Decrease rate of CA19-9, %, > vs. ≤70

0.267

0.090-0.793

0.017

0.309

0.099-0.960

0.042

0.578

0.325-1.030

0.063

Tumor diameter before NACT, cm, > vs. ≤3

1.812

0.649-5.065

0.257

2.189

1.174-4.082

0.014

2.185

1.166-4.097

0.015

RECIST status, partial response vs. stable disease or progressive disease

1.641

0.567-4.746

0.361

1.171

0.651-2.108

0.598

Surgical approach, LPD vs. OPD

0.833

0.260-2.675

0.759

0.715

0.375-1.360

0.306

Transfusion, yes vs. no

1.166

0.412-3.304

0.773

1.321

0.728-2.396

0.360

Superior mesenteric vein / Portal vein resection, yes vs. no

2.333

0.838-6.497

0.105

1.681

0.952-2.969

0.074

Tumor differentiation, poor vs. moderate or well

4.333

1.498-12.532

0.007

3.805

1.271-11.393

0.017

1.819

1.039-3.184

0.036

1.805

1.030-3.163

0.039

Intravascular tumor thrombus, yes vs. no

1.174

0.428-3.220

0.755

1.535

0.865-2.726

0.143

Adjacent tissue invasion, yes vs. no

1.451

0.417-5.049

0.558

1.521

0.775-2.987

0.223

Adjacent organ invasion, yes vs. no

1.312

0.471-3.655

0.603

0.968

0.546-1.715

0.912

Lymph node metastasis, yes vs. no

1.061

0.388-2.902

0.909

1.500

0.854-2.637

0.159

R1 margin, yes vs. no

1.922

0.483-7.640

0.354

1.609

0.713-3.630

0.252